College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon 34134, Korea.
BMB Rep. 2019 Feb;52(2):113-118. doi: 10.5483/BMBRep.2019.52.2.017.
The small ubiquitin-related modification molecule (SUMO), one of the post-translational modification molecules, is involved in a variety of cellular functions where it regulates protein activity and stability, transcription, and cell cycling. Modulation of protein SUMOylation or deSUMOylation modification has been associated with regulation of carcinogenesis in breast cancer. In the dynamic processes of SUMOylation and deSUMOylation in a variety of cancers, SUMO proteases (SENPs), reverse SUMOylation by isopeptidase activity and SENPs are mostly elevated, and are related to poor patient prognosis. Although underlying mechanisms have been suggested for how SENPs participate in breast cancer tumorigenesis, such as through regulation of target protein transactivation, cancer cell survival, cell cycle, or other post-translational modification-related machinery recruitment, the effect of SENP isoform-specific inhibitors on the progression of breast cancer have not been well evaluated. This review will introduce the functions of SENP1 and SENP2 and the underlying signaling pathways in breast cancer for use in discovery of new biomarkers for diagnosis or therapeutic targets for treatment. [BMB Reports 2019; 52(2): 113-118].
小泛素相关修饰物（SUMO）是一种翻译后修饰分子，参与多种细胞功能，调节蛋白质活性和稳定性、转录和细胞周期。蛋白质 SUMO 化或去 SUMO 化修饰的调节与乳腺癌的致癌作用有关。在多种癌症中 SUMO 化和去 SUMO 化的动态过程中，SUMO 蛋白酶（SENPs）通过异构酶活性进行反向 SUMO 化，SENPs 大多升高，并与患者预后不良有关。虽然已经提出了 SENPs 如何参与乳腺癌发生的潜在机制，例如通过调节靶蛋白反式激活、癌细胞存活、细胞周期或其他与翻译后修饰相关的机制募集，但 SENP 同工型特异性抑制剂对乳腺癌进展的影响尚未得到很好的评估。这篇综述将介绍 SENP1 和 SENP2 的功能及其在乳腺癌中的信号通路，用于发现新的诊断生物标志物或治疗靶点。[BMB 报告 2019；52(2): 113-118]。
